Grandfather and grandson with feed in water.

OSTEOCOOL RF ABLATION for the treatment of painful bone tumors

See Clinical Evidence
Alert Indications, Safety, and Warnings

latest news

OUTCOMES IN 100 PATIENTS TREATED

The OsteoCool™ Post-Market Clinical Study (OPuS One) is one of the largest studies in radiofrequency (RF) ablation evaluating outcomes in patients with painful metastatic tumors and benign bone tumors. This multicenter study is collecting real world evidence on the effectiveness and safety of OsteoCool. OPuS One is a global, prospective, non-randomized, single-arm study. Data on the first 100 patients is now available.

See clinical evidence

Patient Feature

Cory's Story

Cory’s breast cancer metastasized to her spine and sacrum causing unrelenting lower back pain that brought her into the ER. Not wanting to remain on opioids for her pain, Cory asked her doctor about other options. Dr. Ramsin Benyamin at Millennium Pain Center in Normal, IL offered to treat Cory’s cancer pain with OsteoCool.

Info for oncologists
Info for proceduralists

View Cory's story regarding her experience with OsteoCool Radiofrequency ablation therapy.
More information (see more) Less information (see less)

Product Overview

The OsteoCool RF ablation system is cooled radiofrequency ablation technology. It offers simultaneous, dual-probe capabilities for treating painful bone tumors, including benign and painful metastatic lesions. The system’s algorithms are designed to perform optimally in bone, allowing you to overcome challenges through a wide range of ablation scenarios, letting you treat patients confidently and consistently.

Learn about the technology
Get Reimbursement Info

Watch the OsteoCool RF Ablation System Procedure Animation
More information (see more) Less information (see less)

Indications, Safety, and Warnings

INDICATIONS

  • Intended for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body
  • Coagulation and ablation of tissue in bone during surgical procedures including palliation of pain associated with metastatic lesions involving bone in patients who have failed or are not candidates for standard therapy
  • Ablation of benign bone tumors such as osteoid osteoma

RISKS

  • As a consequence of electrosurgery, damage to surrounding tissue through iatrogenic injury could occur
  • Pulmonary embolism